4.6 Article

Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Endocrinology & Metabolism

Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system

Hajime Kato et al.

Summary: The study evaluated a new fully automated immunoassay for FGF23 and compared it with a previous assay. The new assay yielded lower FGF23 values compared to the previous one, which clinicians should consider when assessing intact FGF23 values.

JOURNAL OF BONE AND MINERAL METABOLISM (2022)

Article Endocrinology & Metabolism

PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1-34

Diana Ovejero et al.

Summary: The study found that the effects of PTH and FGF23 on phosphate regulation are interdependent, and both are required for adequate renal phosphate handling.

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

Article Endocrinology & Metabolism

Serum Phosphate:A Neglected Test in the Clinical Management of Primary Hyperparathyroidism

Elena Castellano et al.

Summary: This study investigated the relationship between P levels and clinical features of PHPT severity and found that P levels are associated with the severity of PHPT. Even moderate HypoP predicts surgical indication in asymptomatic PHPT patients.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Review Endocrinology & Metabolism

Tumor-Induced Osteomalacia

Pablo Florenzano et al.

Summary: Tumor-induced osteomalacia is a rare paraneoplastic syndrome caused by tumoral production of FGF23, characterized by hypophosphatemia, abnormal vitamin D levels, and elevated FGF23. Treatment includes surgical resection, medical therapy, and novel approaches, but locating the tumor can be challenging.

CALCIFIED TISSUE INTERNATIONAL (2021)

Article Endocrinology & Metabolism

C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23

Kelly Lauter Roszko et al.

Summary: FGF23 is a key hormone regulating phosphate and vitamin D, with complex pathways involved in its physiology. Studies suggest the HIF/EPO pathway may play a direct role in FGF23 transcription and translation. Research in rare cases highlights the finely tuned posttranslational regulation to maintain normal blood phosphate levels despite elevated C-terminal FGF23 levels.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Article Endocrinology & Metabolism

Burosumab for the Treatment of Tumor-Induced Osteomalacia

Suzanne M. Jan de Beur et al.

Summary: The study demonstrated that burosumab exhibited an acceptable safety profile in adult patients with TIO and was associated with improvements in phosphate metabolism and osteomalacia.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Review Endocrinology & Metabolism

FGF23 signalling and physiology

Bryan B. Ho et al.

Summary: FGF23 is a phosphotropic hormone that undergoes post-translational modification by phosphorylation and O-glycosylation, which can lead to either proteolysis or secretion of biologically active intact forms. In the circulation, FGF23 may undergo further processing by other enzymes.

JOURNAL OF MOLECULAR ENDOCRINOLOGY (2021)

Article Endocrinology & Metabolism

Clinical and molecular characterization of Chilean patients with X-linked hypophosphatemia

M. Jimenez et al.

Summary: The most comprehensive clinical and molecular characterization of XLH patients performed in Chile showed high prevalence of musculoskeletal burden and pain, associated with significantly impaired physical capacity and quality of life. These findings suggest a significant unmet need and can inform care for XLH patients in similarly socioeconomically defined countries.

OSTEOPOROSIS INTERNATIONAL (2021)

Review Medicine, Research & Experimental

Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome

John A. Glaspy et al.

Summary: Some intravenous iron formulations can lead to severe hypophosphatemia, especially in patients treated with ferric carboxymaltose. The consequences of severe HPP are usually bone abnormalities. However, there are still uncertainties and limitations in the research on HPP.

ADVANCES IN THERAPY (2021)

Article Endocrinology & Metabolism

Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23

Nobuaki Ito et al.

Summary: The novel FGF23 assay tested in this study showed clinical utility in the differential diagnosis of hypophosphatemic rickets/osteomalacia, effectively distinguishing between different types of hypophosphatemic patients and maintaining good diagnostic sensitivity even in cases with vitamin D deficiency.

JOURNAL OF BONE AND MINERAL METABOLISM (2021)

Article Endocrinology & Metabolism

Impact of Tenofovir Disoproxil-Induced Fanconi Syndrome on Bone Material Quality: A Case Report

Benjamin Hadzimuratovic et al.

Summary: This case report highlights the diagnosis of drug-induced Fanconi syndrome and associated osteomalacia in a 33-year-old female patient treated with Tenofovir for chronic hepatitis B, leading to multiple atraumatic fractures. Analysis using bone biopsy, histomorphometry, and qBEI for bone mineral density distribution was essential in confirming the diagnosis and monitoring the patient's recovery upon cessation of the causative agent.

JBMR PLUS (2021)

Review Urology & Nephrology

FGF23 at the crossroads of phosphate, iron economy and erythropoiesis

Daniel Edmonston et al.

NATURE REVIEWS NEPHROLOGY (2020)

Review Endocrinology & Metabolism

Approach to patients with hypophosphataemia

Pablo Florenzano et al.

LANCET DIABETES & ENDOCRINOLOGY (2020)

Article Urology & Nephrology

Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23

Pablo Florenzano et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Article Endocrinology & Metabolism

Skeletal Consequences of Nephropathic Cystinosis

Pablo Florenzano et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2018)

Article Medicine, General & Internal

Burosumab Therapy in Children with X-Linked Hypophosphatemia

Thomas O. Carpenter et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Review Medical Laboratory Technology

The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper

Khosrow Adeli et al.

CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES (2017)

Article Biochemistry & Molecular Biology

Hypophosphatemia promotes lower rates of muscle ATP synthesis

Dominik H. Pesta et al.

FASEB JOURNAL (2016)

Article Endocrinology & Metabolism

Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment

D. Ovejero et al.

OSTEOPOROSIS INTERNATIONAL (2016)

Review Endocrinology & Metabolism

The PTH-Vitamin D-FGF23 axis

Jenny E. Blau et al.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2015)

Article Urology & Nephrology

Disordered FGF23 and Mineral Metabolism in Children with CKD

Anthony A. Portale et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)

Article Endocrinology & Metabolism

Evaluation of a new automated chemiluminescence immunoassay for FGF23

Yuichiro Shimizu et al.

JOURNAL OF BONE AND MINERAL METABOLISM (2012)

Article Endocrinology & Metabolism

Mechanism of FGF23 processing in fibrous dysplasia

Nisan Bhattacharyya et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2012)

Article Endocrinology & Metabolism

Approach to the Hypophosphatemic Patient

Erik A. Imel et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)

Article Endocrinology & Metabolism

Treatment of X-Linked Hypophosphatemia with Calcitriol and Phosphate Increases Circulating Fibroblast Growth Factor 23 Concentrations

Erik A. Imel et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)

Review Urology & Nephrology

How fibroblast growth factor 23 works

Shiguang Liu et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)

Article Endocrinology & Metabolism

Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia

Erik A. Imel et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)

Article Endocrinology & Metabolism

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

Y Yamazaki et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)